Par Pharmaceutical Companies PRX
-
Par Posts a Loss on Non-Recurring Items, but Generic Launches Should Improve Year-End Results
Par Pharmaceuticals PRX reported a first-quarter loss of $0.79 per share, which includes a $45 million settlement charge with the Department of …
-
UPDATE 1-Par Pharma 1st-qtr beats estimates
May 8 (Reuters) - Par Pharmaceutical Companies Inc, which is under pressure from an activist investor to consider selling itself, posted higher-than-expected results for the fourth straight quarter as most of its products sold well.
-
Pharmaceutical Resources ( PRX ): Q1 EPS of $0.80 beats by $0.08. Revenue of $272M (+17% Y/Y) beats by $42M. (PR)
Pharmaceutical Resources ( PRX ): Q1 EPS of $0.80 beats by $0.08 . Revenue of $272M (+17% Y/Y) beats by $42M . ( PR ) Post your comment!
-
Stifel Nicolaus Sees An Opportunity In Horizon Pharma Shares
By Ben Yoffe : Horizon Pharma ( HZNP ) is a biopharmaceutical company that is developing and commercializing medicines for the treatment of arthritis, pain, and inflammatory diseases. The company offers Duexis for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to
-
Par Pharmaceutical Companies , Inc. PRX Q1 2012 Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Par Pharmaceutical Company's First Quarter Earnings Conference Call. My name is Sue and I ll be your operator for today. At this time, all participants are in listen-only mode. We will conduct a question-and-answer session towards the end of the ...
-
Biotechnology And Drugs Stocks To Watch Next Week
By StockPandit : Next week is a busy earnings season, with many quarterly earnings releases scheduled and a bunch of stocks to watch. However, my focus is on biotechnology and drugs stocks that have earnings due in the next week. This article provides earnings previews on several stocks to consider
-
Valeant: Ready To Move On Increased R&D
By Stock Croc : Valeant ( VRX ) is an unusual biopharma company because it acquires aggressively and and at times inhabits the home of its "host." Puns aside, the company has outgrown its current location acquired from BioVail. Valeant lacked the space for new dermatology R&D research. It also ...
-
DepoMed (DEPO) files a lawsuit againt Impax Laboratories (IPXL) and Par Pharmaceutical ( PRX ) for patent infringement covering ANDAs filed by the firms to market generic versions of Gralise. The ...
DepoMed ( DEPO ) files a lawsuit againt Impax Laboratories ( IPXL ) and Par Pharmaceutical ( PRX ) for patent infringement covering ANDAs filed by the firms to market generic versions of Gralise. The company fired up a previous …
-
4 Pharmaceuticals Making Moves To Boost Profits
By ValueMax : Even though it has been a disappointing week for Spectrum Pharmaceuticals ( SPPI ) , the company does have some good news to report. In the wake of the failure of two clinical trials conducted to test the effectiveness of apaziquone, an experimental bladder cancer drug, the company ...
-
Winning Long-Term Plays In Generic Drugs
By ValueMax : Teva Pharmaceutical Industries ( TEVA ), based in Israel, is a worldwide leader in generic drug manufacturing. Generic drugs are less expensive than their brand-name equivalents, but typically provide the same or similar results. Many people, especially those with inadequate or no ...